In accordance with the “Notice of the General Office of the Ministry of Ecology and Environment and the General Office of the National Development and Reform Commission on Deepening the Promotion of Clean Production Audits in Key Industries” (Huanban Kecai [2020] No. 27), the “Notice of the General Office of the People's Government of the Autonomous Region on Issuing the "Reform Action Plan of the Ningxia Hui Autonomous Region for Strengthening the Supervision, Utilization, and Disposal Capacity of Hazardous Waste" (Ningzhengban Guifa [2022] No. 9), and the “14th Five-Year Plan for the Prevention and Control of Environmental Pollution from Industrial Solid Waste in the Ningxia Hui Autonomous Region”, the Department of Ecology and Environment of the Ningxia Hui Autonomous Region issued the "Notice on Strengthening Mandatory Clean Production Audits for Hazardous Waste-Generating Entities in 2025" on June 17, 2025. This notice mandated that entities generating 100 tons or more of hazardous waste annually undergo mandatory clean production audits. Subsequently, on September 11, 2025, through the "Notice on Announcing the List of Key Enterprises for the Second Batch of Mandatory Clean Production Audits in 2025" (Ninghuanfa [2025] No. 74), Ningxia Qiyuan Pharmaceutical Co., Ltd. was designated as one of the key enterprises for the second batch of mandatory clean production audits in 2025. Consequently, the Company commenced the current round of clean production audit work in October 2025.
I. Basic Profile of the Enterprise
Ningxia Qiyuan Pharmaceutical Co., Ltd. was established through the restructuring and merger of the former Ningxia Pharmaceutical Factory and Ningxia Traditional Chinese Medicine Factory; it is a pharmaceutical enterprise with a history spanning over 60 years. Following its restructuring, the enterprise achieved rapid growth—bolstered by its acute market insight, robust R&D and production capabilities, as well as an advanced management model and a highly efficient management team—and has since emerged as one of the leading biopharmaceutical enterprises in China. The Company occupies a total area of 1,680 mu and employs nearly 1,000 staff members, ranking as one of the key industrial enterprises within the Autonomous Region. 1. Company Name: Ningxia Qiyuan Pharmaceutical Co., Ltd.
2. Legal Representative: Wu Yongming
3. Company Address: No. 1 Qiyuan Avenue, Wangyuan Industrial Park, Yinchuan City, Ningxia
4. Main Products and Production Scale: Tetracycline Hydrochloride (2,000 t/a); Vitamin C (20,000 t/a)
5. Primary Energy Consumption (2022–2024):
6. Hazardous Waste Disposal Status:
In accordance with the requirements of the "Law of the People's Republic of China on Promoting Clean Production" and the "Measures for Clean Production Auditing", we hereby publicly disclose the company's basic profile and its status regarding pollutant generation and discharge. We invite all sectors of society to oversee the company's implementation of its clean production audit.
Copyright © Ningxia Qiyuan Pharmaceutical Co., Ltd 2026. All right reserved.
